Keyphrases
Acute Leukemia
74%
Acute Lymphoblastic Leukemia
69%
Acute Myeloid Leukemia
79%
Acute Promyelocytic Leukemia
31%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
72%
Aplastic Anemia
23%
Bone Marrow
24%
Bone Marrow Transplantation
25%
Burkitt Lymphoma
41%
Chemotherapy
100%
Chronic Lymphocytic Leukemia
93%
Chronic Myeloid Leukemia
70%
Clonal Evolution
32%
Combination Chemotherapy
30%
Complete Remission
41%
Confidence Interval
28%
Environmental Factors
23%
Fluorescence in Situ Hybridization
24%
Gaza Strip
23%
Hematological Malignancies
42%
High Dose
27%
High Risk
41%
Hodgkin Disease
66%
Imatinib
30%
Interferon-α (IFN-α)
39%
Israel
37%
Leukemia
77%
Leukemia Patients
78%
Leukemic Cells
25%
Lymphocytes
38%
Lymphoma
42%
Malignancy
31%
Medical Center
32%
Meta-analysis
58%
Multiple Myeloma
34%
Non-Hodgkin Lymphoma
64%
Overall Survival
30%
Radiotherapy
26%
Red Cells
25%
Reduced-intensity Conditioning
31%
Relative Risk
37%
Remission
41%
Rituximab
33%
SHEBA
34%
Stem Cell Transplantation
39%
Systematic Meta-analysis
49%
T Cells
46%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
40%
Treatment Results
23%
Tumor
32%
Medicine and Dentistry
Acute Leukemia
65%
Acute Lymphoblastic Leukemia
88%
Acute Myeloid Leukemia
54%
Acute Promyelocytic Leukemia
26%
Adriamycin Bleomycin Vinblastine Dacarbazine
19%
Adverse Event
17%
Allogeneic Hematopoietic Stem Cell Transplantation
23%
Allogeneic Stem Cell Transplantation
24%
Aplastic Anemia
21%
Autologous Stem Cell Transplantation
19%
B-Cell Chronic Lymphocytic Leukemia
50%
Burkitt's Lymphoma
32%
Busulfan
19%
Cancer
30%
Chronic Myelogenous Leukemia
34%
Combination Chemotherapy
19%
Disease
99%
Environmental Factor
25%
Ferritin
15%
Glucose 6 Phosphate Dehydrogenase
17%
Hematologic Malignancy
32%
Hemolytic Anemia
20%
Hodgkin's Lymphoma
84%
Immunoglobulin
24%
Immunoglobulin Heavy Chain
19%
Infection
35%
Interferon
23%
Leukemia
60%
Lymphocyte
48%
Lymphoproliferative Disease
27%
Meta-Analysis
35%
Multiple Myeloma
24%
Neoplasm
27%
Neutropenia
17%
Non-Hodgkin Lymphoma
61%
Oncology
15%
Overall Survival
18%
Pediatrics
21%
Plasmacytoma
23%
Platelet
17%
Positron Emission Tomography-Computed Tomography
26%
Radiation Therapy
33%
Reduced Intensity Conditioning
31%
Rituximab
25%
Rosette Formation
15%
Stem Cell Therapy
19%
Systematic Review
25%
T Cell
28%
Tretinoin
19%
Vincristine
17%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Leukemia
47%
Acute Lymphoblastic Leukemia
39%
Acute Myeloid Leukemia
64%
Adverse Event
26%
All Cause Mortality
15%
Aplastic Anemia
21%
Bleomycin
21%
Burkitt's Lymphoma
17%
Busulfan
15%
Chemotherapy
63%
Chronic Lymphatic Leukemia
25%
Chronic Myeloid Leukemia
46%
Colony Stimulating Factor
15%
Cyclophosphamide
19%
Cytarabine
23%
Cytokine
11%
Disease
65%
Disease Free Survival
15%
Doxorubicin
22%
Graft Versus Host Reaction
10%
Hematologic Disease
11%
Hematologic Malignancy
30%
Hemopoietic Growth Factor
15%
Hereditary Hemolytic Anemia
9%
Hodgkin Disease
31%
Ibritumomab Tiuxetan
15%
Imatinib
30%
Immunoglobulin
29%
Infection
41%
Infectious Complication
15%
Interferon
31%
Leukemia
51%
Lymphoproliferative Disease
10%
Multiple Myeloma
17%
Myelodysplastic Syndrome
10%
Neoplasm
10%
Nonhodgkin Lymphoma
57%
Overall Survival
22%
Prednisone
21%
Procarbazine
14%
Progression Free Survival
10%
Promyelocytic Leukemia
20%
Protein Tyrosine Kinase Inhibitor
11%
Randomized Controlled Trial
13%
Remission
62%
Retinoic Acid
15%
Rituximab
25%
Thrombocytopenia
11%
Vein Occlusion
12%
Vincristine
31%